Find research, discussions, posts, companies, and topics.
Search uses Goglides API results from the projection-backed discovery index. Private, draft, hidden, unpublished, and admin-only content stays out of public results.
A beginner-friendly translation of Datavault AI's $2.0B structured financing term sheet, including term sheet status, dilution, tranches, the $25M payment, share-value math, and shareholder proof gates.
A source-backed Datavault AI analysis that separates the real May 2026 institutional financing signal from unsupported dark-pool, hedge-fund, bank-upgrade, and supply-crunch claims.
A beginner-friendly, fact-based DVLT brief on HELMEX, the UK address controversy, the non-binding $2B term sheet, the $25M payment, dilution, and board rights.
20/20 Biolabs has a real OneTest cancer-screening revenue base and a fresh Nasdaq listing, but FY2025 losses, negative cash flow, Streeterville financing and resale overhang keep AIDX in a high-risk coverage bucket.
Aditxt's filings show a precommercial health-innovation platform with immune, diagnostic, infectious-disease, women's-health, and proteomics ambitions, but the source-backed decision point is Nasdaq survival, cash, dilution, and whether any program can outrun
Aclarion has a distinctive MRS-based spine diagnostic workflow, a stronger post-financing cash balance, and visible CLARITY and payer proof gates, but FY2025 revenue was only $75,730 and the company still has to convert Nociscan from clinical promise into reim
Agilent's CrossLab mix and cash generation point to a durable lab-workflow franchise, but the open question is whether service and consumables strength can outrun instrument-cycle volatility.
A filing-led Datavault AI deep dive covering Q1 2026 results, product architecture, RWA tokenization, SanQtum GPU infrastructure, NYIAX/CyberCatch/DelivMeds optionality, HELMEX structured financing, dilution, and the proof gates that matter next.
Zevra Therapeutics, Inc. has an official-source baseline, but the report keeps the decision focused on filings: revenue quality, operating income, cash conversion, balance-sheet risk and the next update.
Yum China reported FY2025 revenue of $11.8 billion and Q1 2026 revenue of $3.3 billion. The thesis depends on same-store demand, restaurant expansion, delivery economics, China consumer conditions, margin control and capex discipline.
Yatra Online, Inc. has an official-source baseline, but the report keeps the decision focused on filings: revenue quality, operating income, cash conversion, balance-sheet risk and the next update.
Yesway, Inc. has an official-source baseline, but the report keeps the decision focused on filings: revenue quality, operating income, cash conversion, balance-sheet risk and the next update.
Zentalis Pharmaceuticals, Inc. has an official-source baseline, but the report keeps the decision focused on filings: revenue quality, operating income, cash conversion, balance-sheet risk and the next update.
Zoom reported FY2026 revenue of $4.9 billion and Q3 FY2026 revenue of $1.2 billion. The thesis depends on enterprise retention, Zoom Phone, contact center, AI features, margin durability and cash conversion.
Kinder Morgan reported 2025 revenue of $15.20 billion, operating income of $4.72 billion and operating cash flow of $5.92 billion. The Coverage Bootstrap question is whether natural-gas infrastructure cash flow can keep funding dividends and projects without l
Clear Secure reported FY2025 revenue of $900.8 million and Q1 2026 revenue of $253.0 million, with the official record tying the thesis to airport-member growth, identity platform expansion, deferred revenue, privacy trust, margin quality and cash conversion.
ZipRecruiter, Inc. has an official-source baseline, but the report keeps the decision focused on filings: revenue quality, operating income, cash conversion, balance-sheet risk and the next update.